Skip to content
Screener

Erasca, Inc. ERAS Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$861M-150%
Eli Lilly logo
Eli LillyLLY
$3.67B+1,196%
Pfizer logo
PfizerPFE
$563M+50.1%
Amgen logo
AmgenAMGN
$1.95B+349%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$374.5M
Tango Therapeutics logo
Tango TherapeuticsTNGX
$45.12M+507%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Cash flows from financing activities:
Proceeds from issuance of common stock in underwritten offering258,750
Issuance costs associated with underwritten offering(16,044)
Proceeds from the exercise of stock options1,95833
Net cash provided by financing activities244,66433
Net (decrease) increase in cash, cash equivalents, and restricted cash(26,549)2,743
Cash, cash equivalents, and restricted cash at beginning of the period74,21368,147
Cash, cash equivalents, and restricted cash at end of the period$47,664$70,890

Item 1. Financial Statements.

FAQ

What is Erasca, Inc.'s net change in cash?
Erasca, Inc. (ERAS) reported net change in cash of -$26.55M in Q1 2026.
How has Erasca, Inc.'s net change in cash changed year-over-year?
Erasca, Inc.'s net change in cash decreased by 1067.9% year-over-year, from $2.74M to -$26.55M.
What is the long-term trend for Erasca, Inc.'s net change in cash?
Over 2 years (2023 to 2025), Erasca, Inc.'s net change in cash has grown at a -82.2% compound annual growth rate (CAGR), from -$191.14M to $6.07M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Erasca, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude